CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes

Drug Metabolism and Disposition

Volumn 28, Issue 3, 2000, Pages 354-359

  Wester, Michael R ^a,c   Lasker, Jerome M ^b   Johnson, Eric F ^c   Raucy, Judy L ^d  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d La Jolla Institute for Experimental Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; DICLOFENAC; MEPHENYTOIN; ORAL ANTIDIABETIC AGENT; POLYCLONAL ANTIBODY; TOLBUTAMIDE;

ARTICLE; CATALYST; CONTROLLED STUDY; DRUG DISPOSITION; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCHEMISTRY; LIVER MICROSOME; PRIORITY JOURNAL; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ARYL HYDROCARBON HYDROXYLASES; CROSS REACTIONS; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; HUMANS; HYDROXYLATION; MALE; MEPHENYTOIN; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; RABBITS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TOLBUTAMIDE;

EID: 0034010930     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Forrester LM, Henderson CJ, Glancey MJ, Back DJ, Park BK, Ball SE, Kitteringham NR, McLaren AW, Miles JS and Skett P (1992). Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 281:359-368.
2. Guengerich FP, Hosea NA, Parikh A, Bell-Parikh LC, Johnson WW, Gillam EMJ and Shimada T (1998) Twenty years of biochemistry of human P450s - Purification, expression, mechanism, and relevance to drugs. Drug Metab Dispos 26:1175-1178.
3. Hall SD, Hamman MA, Rettie AE, Wienkers LC, Trager WF, Vandenbranden M and Wrighton SA (1994) Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. Drug Metab Dispos 22:975-978.
4. Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP and Shimada T (1997) Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics 7:103-113.
5. Knodell RG, Hall SD, Wilkinson GR and Guengerich FP (1987) Hepatic metabolism of tolbutamide: Characterization of the form of cytochrome P450 involved in methylhydroxylation and relationship to in vivo disposition. J Pharmacol Exp Ther 241:1112-1119.
6. Lasker JM, Wester MR, Aramsombatdee E and Raucy JL (1998) Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Arch Biochem Biophys 353:16-28.
7. Leemann T, Transon C and Dayer P (1993) Cytochrome P450TB (CYP2C): A major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52:29-34.
8. Meier UT, Kronbach T and Meyer UA (1985) Assay of mephenytoin metabolism in human microsomes by high performance liquid chromatography. Anal Biochem 151:286-291.
9. Newton DJ, Wang RW and Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
10. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
11. Raucy JL and Lasker JM (1991) Isolation of P450 enzymes from human liver. Methods Enzymol 206:577-587.
12. Richardson TH, Jung F, Griffin KJ, Wester M, Raucy JL, Kemper B, Bornheim LM, Hassett C, Omiecinksi CJ and Johnson EF (1995) A universal approach to the expression of human and rabbit cytochrome P450s of the 2C subfamily in Escherichia coli. Arch Biochem Biophys 323:87-96.
13. Romkes M, Faletto MB, Blaisdell JA, Raucy JL and Goldstein JA (1991) Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 30:3247-3255.
14. Scott J and Poffenbarger PL (1979) Pharmacogenetics of tolbutamide metabolism in humans. Diabetes 28:41-51.
15. Shimada T, Misono KS and Guengerich FP (1986) Human liver microsomal cytochrome P450 mephenytoin 4′-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J Biol Chem 261:909-921.
16. Shimada T, Shea JP and Guengerich FP (1985) A convenient assay for mephenytoin 4′-hydroxylase activity of human liver microsomal cytochrome P-450. Anal Biochem 147:174-179.
17. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85.
18. Srivastava PK, Yun CH, Beaune PH, Ged C and Guengerich FP (1991) Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol 40:69-79.
19. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341-349.
20. Venkatakrishnan K, von Moltke LL and Greenblatt DJ (1998) Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: Application of the relative activity factor approach. J Pharm Sci 87:845-853.
21. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO and Birkett DJ (1991) Tolbutami le and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 175:1112-1118.